BIOVECTRA acquired by AGILENT TECHNOLOGIES

Sanofi has announced the sale of 50% of its stake in Opella to the American fund CD&R. Opella Healthcare (formerly Sanofi Consumer Healthcare) is a company specializing in consumer healthcare products.

Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO. The existing executive management team will continue to operate the business independently. The strategic rationale centres on accelerating PetIQ's mission of providing convenient and affordable pet healthcare, investing in marketing and innovation, and pursuing strategic bolt-on acquisitions — initiatives that Bansk believes are better executed outside the constraints of public market ownership

Recursion Pharmaceuticals has entered into a definitive agreement to acquire Exscientia in an all-stock transaction. This strategic move aims to bring together two artificial intelligence-driven drug discovery specialists, creating a comprehensive platform that spans the entire process, from biology to computational chemistry. The deal is structured as a stock swap, where Recursion shareholders will hold the majority of the combined entity's capital, while Exscientia shareholders will receive a minority stake in the new company

Nordson Corporation completed its acquisition of Atrion Corporation on August 21, 2024, following the definitive agreement announced on May 28, 2024. The strategic rationale is centered on portfolio expansion within Nordson Medical. Atrion adds proprietary infusion fluid delivery and niche cardiovascular technologies, broadening Nordson’s exposure to adjacent end markets and strengthening its offering in higher-growth medical applications. The combination is highly complementary from both a product and customer standpoint, while also benefiting from Atrion’s FDA-registered manufacturing footprint and patent portfolio

The acquisition of the point-of-care technology platform from the LumiraDx group marks a transformative technical reinforcement of the acquirer's diagnostic ecosystem. The strategic rationale for this transaction centers on a "decentralization" play, merging the target's innovative multi-assay hardware with the group’s vast global commercial and R&D infrastructure. This fusion effectively creates a comprehensive solution set for primary care and remote settings, addressing the global need for timely and affordable diagnostic results outside of centralized facilities

The successful acquisition of ELITechGroup by Bruker Corporation marks a definitive tactical expansion of the group's microbiology and infection diagnostics portfolio. This transaction facilitates the integration of ELITech’s innovative sample-to-result molecular diagnostic systems with Bruker’s existing microbial identification capabilities. The strategic rationale for the move centers on the fusion of ELITech’s specialized PCR assay technology and Bruker’s global reach and industrialized R&D machine

GTCR agreed to acquire Surmodics as a take-private acquisition, financed through committed equity from GTCR-affiliated funds and committed debt financing. The strategic rationale rests on Surmodics’ position as a specialized healthcare technology platform with recurring exposure to medical device coatings and in vitro diagnostics. The business has a long track record of serving blue-chip customers, and its proprietary technologies are aligned with secular healthcare growth drivers including aging demographics, minimally invasive procedures, and OEM outsourcing

Kühne Holding AG has entered into a definitive agreement to acquire a majority stake in Aenova Group from the international investment firm BC Partners. In a move to ensure continuity and strategic alignment, funds advised by BC Partners will reinvest alongside Kühne Holding to maintain a minority position in the company. The transaction was structured and executed in close partnership with E3X Partners, acting as the lead advisor and investment partner for the Kühne family vehicle. The strategic rationale for the acquisition is focused on expanding Kühne Holding’s portfolio into the pharmaceutical services sector, attracted by Aenova’s strong financial foundation and long-term growth prospects

The acquisition of Peters Surgical by Advanced Medical Solutions Group plc is a strategic move to expand AMS's portfolio of surgical products and strengthen its presence in the global wound closure and tissue repair market. The transaction will enable Peters Surgical to benefit from complementary product portfolios, sales forces, commercial presence, and distribution networks. The acquisition is expected to create a leading player in the advanced wound closure and surgical closure market, with a comprehensive portfolio of products and a strong global presence

Merck has entered into a definitive agreement to acquire 100% of the outstanding shares of Harpoon Therapeutics. Strategically, this acquisition allows Merck to further diversify its oncology pipeline by integrating Harpoon’s proprietary TriTAC and ProTriTAC T-cell engager platforms. The rationale for the deal centers on the potential of the lead candidate, HPN328, which targets DLL3 in small cell lung cancer and neuroendocrine tumors, providing Merck with a highly complementary asset for its existing immunotherapy portfolio